Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720994 | 0.93 | SLC1A3 (0.44) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL23723780 | 0.90 | RCE1 (0.50) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL10718173 | 0.87 | PPARG (0.43) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL10719263 | 0.87 | CETP (0.47) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL9662131 | 0.85 | CETP (0.49) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL7155541 | 0.85 | MAPT (0.53) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL17663535 | 0.85 | MAPT (0.53) | SLC1A3SLC1A2SLC1A1KMT2AMEN1 | |
| SCHEMBL10717717 | 0.84 | CETP (0.51) | KMT2AMEN1CYP2C9CYP2C19TSHR | |
| SCHEMBL10717605 | 0.84 | CETP (0.51) | KMT2AMEN1CYP2C9CYP2C19TSHR | |
| SCHEMBL10717589 | 0.84 | CETP (0.51) | KMT2AMEN1CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111961077-B | Preparation method of beta sodium glycerophosphate containing crystal water | 山西千岫制药有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111961077-A | Preparation method of beta sodium glycerophosphate containing crystal water | 山西千岫制药有限公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3353183-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3]THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL]AMIDES | Pfizer Inc (US) | 2018-08-01 | — | — | EP | disclosed |
| CN-108135188-A | For the precursor compound of molecular coatings | 阿比尔技术公司 | 2018-06-08 | — | — | CN | disclosed |
| WO-2017051276-A1 | N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES | PFIZER INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-3083604-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | Respivert Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| EP-3007727-A1 | POLYDENDRONS | The University of Liverpool (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2931838-A1 | LIQUID-CRYSTAL DISPLAYS AND LIQUID-CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT | Merck Patent GmbH (DE) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015092423-A1 | UREA DERIVATIVES USEFUL AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014199174-A1 | POLYDENDRONS | THE UNIVERSITY OF LIVERPOOL (GB) | 2014-12-18 | — | — | WO | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007144327-A2 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007140483-A2 | FILMS AND PARTICLES | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| EP-1181017-A1 | METALLOPROTEASE INHIBITORS | Pfizer Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| EP-1061954-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES WITH PROXIMAL REACTIVE GROUPS | Shearwater Polymers, Incorporated (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000074681-A1 | METALLOPROTEASE INHIBITORS | PFIZER LIMITED (GB) | 2000-12-14 | — | — | WO | disclosed |
| EP-0988304-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999045964-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES WITH PROXIMAL REACTIVE GROUPS | SHEARWATER POLYMERS, INCORPORATED (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999009031-A1 | NUCLEOSIDES ANALOGUES, SUCH AS ANTIVIRALS INCLUDING INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTASE AND THE DNA POLYMERASE OF HEPATITIS B VIRUS (HBV) | MEDIVIR AB (SE) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | SLC1A3 1469/4885SLC1A2 3805/4885SLC1A1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.